Boone Capital Management LLC Invests $39,000 in Astrazeneca Plc $AZN

Boone Capital Management LLC acquired a new position in shares of Astrazeneca Plc (NYSE:AZN) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 220,201 shares of the company’s stock, valued at approximately $39,000. Astrazeneca accounts for about 0.0% of Boone Capital Management LLC’s holdings, making the stock its 15th largest holding.

Several other large investors have also modified their holdings of the company. Visionary Wealth Advisors boosted its holdings in shares of Astrazeneca by 1.5% during the 4th quarter. Visionary Wealth Advisors now owns 4,197 shares of the company’s stock worth $737,000 after buying an additional 60 shares during the period. Kestra Investment Management LLC boosted its holdings in shares of Astrazeneca by 1.9% during the 4th quarter. Kestra Investment Management LLC now owns 3,391 shares of the company’s stock worth $595,000 after buying an additional 63 shares during the period. Luken Investment Analytics LLC boosted its holdings in shares of Astrazeneca by 4.3% during the 4th quarter. Luken Investment Analytics LLC now owns 1,564 shares of the company’s stock worth $274,000 after buying an additional 64 shares during the period. Addison Advisors LLC boosted its holdings in shares of Astrazeneca by 3.9% during the 4th quarter. Addison Advisors LLC now owns 1,736 shares of the company’s stock worth $305,000 after buying an additional 65 shares during the period. Finally, Western Wealth Management LLC boosted its holdings in shares of Astrazeneca by 2.5% during the 4th quarter. Western Wealth Management LLC now owns 2,887 shares of the company’s stock worth $507,000 after buying an additional 71 shares during the period. 20.35% of the stock is owned by institutional investors.

Astrazeneca Price Performance

Shares of Astrazeneca stock opened at $178.09 on Thursday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. Astrazeneca Plc has a fifty-two week low of $137.23 and a fifty-two week high of $212.71. The firm has a fifty day moving average price of $187.81 and a two-hundred day moving average price of $186.21. The company has a market cap of $276.20 billion, a PE ratio of 26.74, a price-to-earnings-growth ratio of 1.55 and a beta of 0.25.

Astrazeneca (NYSE:AZN) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The firm had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. Analysts expect that Astrazeneca Plc will post 9.39 EPS for the current year.

Analyst Ratings Changes

Several analysts recently issued reports on AZN shares. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a report on Tuesday, June 9th. UBS Group reaffirmed a “buy” rating on shares of Astrazeneca in a report on Friday, April 10th. TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Wall Street Zen raised shares of Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Finally, JPMorgan Chase & Co. reissued a “buy” rating on shares of Astrazeneca in a report on Tuesday, June 9th. Twelve research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Astrazeneca presently has an average rating of “Moderate Buy” and a consensus target price of $205.33.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.